CSL CFO to lead flu vaccine business after 2016 launch

Australia's CSL will launch its new global flu vaccine business in early 2016, after it completes its $275 million acquisition of Novartis' ($NVS) flu vaccine unit. CSL's chief financial officer, Gordon Naylor, will head the new business. Combined, the Novartis business and CSL's flu vaccine subsidiary, bioCSL, will be the world's second-largest flu vaccine supplier. More

Read more on